Irisin in metabolic diseases.
Title | Irisin in metabolic diseases. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z. A., Makras P., Perakakis N., Kountouras J., & Mantzoros C. S. |
Journal | Endocrine |
Volume | 59 |
Issue | 2 |
Pagination | 260-274 |
Date Published | 2018 02 |
ISSN | 1559-0100 |
Keywords | Adipose Tissue, White, Adiposity, Bone Density, Fibronectins, Humans, Metabolic Diseases, Muscle, Skeletal |
Abstract | INTRODUCTION: Irisin is a myokine/adipokine induced by the exercise in mice and humans, which is proposed to induce "browning" of white adipose tissue, its primary target, thus increasing thermogenesis and energy expenditure. Since its identification, irisin has been linked to favorable effects on metabolic diseases, including obesity, type 2 diabetes mellitus (T2DM), lipid metabolism and cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), and metabolic bone diseases. Generally, despite the promising profile of irisin in rodents, its effects on human are less recognized. |
DOI | 10.1007/s12020-017-1476-1 |
Alternate Journal | Endocrine |
PubMed ID | 29170905 |